{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:10:46Z","timestamp":1788901846316,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008425","name":"Conseller\u00eda de Cultura, Educaci\u00f3n e Ordenaci\u00f3n Universitaria, Xunta de Galicia","doi-asserted-by":"publisher","award":["ED481A-2017\/087"],"award-info":[{"award-number":["ED481A-2017\/087"]}],"id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016658","name":"Plan Nacional sobre Drogas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["2021-PG054"],"award-info":[{"award-number":["2021-PG054"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:17:06Z","timestamp":1788812226000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["How safe is occupational exposure to citostatic drugs? Results from environmental and biological monitoring"],"prefix":"10.1016","author":[{"given":"Jos\u00e9 \u00c1ngel","family":"Lema-At\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lendoiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelines","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bernardez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Cobo-Golpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Blanco-Ces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Tour\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"L\u00f3pez-Rabu\u00f1al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"L\u00f3pez-Rivadulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"de-Castro-R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.farma.2026.06.012_bb0005","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00204-023-03481-9","article-title":"Systematic review of genotoxicity induced by occupational exposure to antineoplastic drugs","volume":"97","author":"Vanneste","year":"2023","journal-title":"Arch Toxicol"},{"issue":"12","key":"10.1016\/j.farma.2026.06.012_bb0010","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1111\/jocn.17488","article-title":"Global cancer nurse's experiences and perceptions of potential occupational exposure to cytotoxic drugs: Mixed method systematic review with framework synthesis","volume":"33","author":"Campbell","year":"2024","journal-title":"J Clin Nurs"},{"issue":"1","key":"10.1016\/j.farma.2026.06.012_bb0015","article-title":"Biological monitoring of the oncology healthcare staff exposed to cyclophosphamide in two hospitals in Tehran","volume":"12","author":"Azari","year":"2019","journal-title":"Int J Cancer Manag"},{"key":"10.1016\/j.farma.2026.06.012_bb0020","unstructured":"European Biosafety Network. Amendments to the Carcinogens and Mutagens Directive on hazardous drugs and implications for change to the healthcare system in Europe to ensure compliance with its requirements. https:\/\/www.europeanbiosafetynetwork.eu\/wp-content\/uploads\/2019\/03\/Amendments-to-CMD3-and-implications.pdf. Published in 2019. Access 4 January 2025."},{"key":"10.1016\/j.farma.2026.06.012_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1235496","article-title":"Proposals of guidance values for surface contamination by antineoplastic drugs based on long term monitoring in Czech and Slovak hospitals and pharmacies","volume":"11","author":"Bl\u00e1hov\u00e1","year":"2023","journal-title":"Front Public Health"},{"issue":"7","key":"10.1016\/j.farma.2026.06.012_bb0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1078155217704990","article-title":"Carry-over of antineoplastic drug contamination in Dutch hospital pharmacies","volume":"24","author":"Crul","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.farma.2026.06.012_bb0035","first-page":"444","article-title":"Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project","volume":"57","author":"Kiffmeyer","year":"2013","journal-title":"Ann Occup Hyg"},{"issue":"8","key":"10.1016\/j.farma.2026.06.012_bb0040","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/annweh\/wxx065","article-title":"Monitoring surface contamination by antineoplastic drugs in Italian hospitals: performance-based hygienic guidance values (HGVs) project","volume":"61","author":"Sottani","year":"2017","journal-title":"Ann Work Expo Health"},{"issue":"6","key":"10.1016\/j.farma.2026.06.012_bb0045","first-page":"589","article-title":"Analytical strategies for assessing occupational exposure to antineoplastic drugs in healthcare workplaces","volume":"69","author":"Dugheri","year":"2018","journal-title":"Med Pr"},{"issue":"5","key":"10.1016\/j.farma.2026.06.012_bb0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.13075\/mp.5893.01288","article-title":"Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs)","volume":"73","author":"Dugheri","year":"2022","journal-title":"Med Pr"},{"key":"10.1016\/j.farma.2026.06.012_bb0055","first-page":"2","article-title":"Environmental contamination with cytotoxic drugs in 15 hospitals from 11 European countries\u2014results of the MASHA project","volume":"3","author":"Korczowska","year":"2020","journal-title":"Eur J Oncol Pharm"},{"key":"10.1016\/j.farma.2026.06.012_bb0060","first-page":"3","article-title":"Protecting the health care workforce from cytotoxic drugs contamination in the hospital wards: the results of the pan-European MASHA-2 project","volume":"6","author":"Korczowska","year":"2023","journal-title":"Eur J Oncol Pharm"},{"issue":"2","key":"10.1016\/j.farma.2026.06.012_bb0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1078155214522840","article-title":"Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation","volume":"21","author":"Sessink","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.farma.2026.06.012_bb0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/19338244.2013.763757","article-title":"Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies","volume":"69","author":"Odraska","year":"2014","journal-title":"Arch Environ Occup Health"},{"issue":"9","key":"10.1016\/j.farma.2026.06.012_bb0075","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/jat\/bkac073","article-title":"LC\u2013MS-MS determination of cytostatic drugs on surfaces and in urine to assess occupational exposure","volume":"46","author":"Lema-At\u00e1n","year":"2022","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.farma.2026.06.012_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.00374","article-title":"Environmental contamination and occupational exposure of Algerian hospital workers","volume":"8","author":"Verscheure","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.farma.2026.06.012_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxlet.2018.05.002","article-title":"Environmental and biological monitoring on an oncology ward during a complete working week","volume":"298","author":"Koller","year":"2018","journal-title":"Toxicol Lett"},{"issue":"8","key":"10.1016\/j.farma.2026.06.012_bb0090","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/annweh\/wxx070","article-title":"Wipe sampling method and evaluation of environmental variables for assessing surface contamination of 10 antineoplastic drugs by liquid chromatography\/tandem mass spectrometry","volume":"61","author":"Colombo","year":"2017","journal-title":"Ann Work Exposures Health"},{"key":"10.1016\/j.farma.2026.06.012_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpba.2019.04.042","article-title":"Validation and uncertainty estimation for trace amounts determination of 25 drugs used in hospital chemotherapy compounding units","volume":"172","author":"Guichard","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.farma.2026.06.012_bb0100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.13075\/mp.5893.00931","article-title":"Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces","volume":"71","author":"Mucci","year":"2020","journal-title":"Med Pr"},{"issue":"8","key":"10.1016\/j.farma.2026.06.012_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080754","article-title":"An improved LC\u2013MS\/MS method for the analysis of thirteen cytostatics on workplace surfaces","volume":"14","author":"Portilha-Cunha","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.farma.2026.06.012_bb0110","first-page":"368","article-title":"Biological monitoring of nurses exposed to doxorubicin and epirubicin by a validated liquid chromatography\/fluorescence detection method","volume":"54","author":"Pieri","year":"2010","journal-title":"Ann Occup Hyg"},{"issue":"1","key":"10.1016\/j.farma.2026.06.012_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1078155210380485","article-title":"Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan","volume":"17","author":"Yoshida","year":"2011","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.farma.2026.06.012_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/2193-1801-2-273","article-title":"Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital","volume":"2","author":"Miyake","year":"2013","journal-title":"Springerplus"},{"issue":"3","key":"10.1016\/j.farma.2026.06.012_bb0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1310\/hpj4803-204","article-title":"Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device","volume":"48","author":"Sessink","year":"2013","journal-title":"Hosp Pharm"},{"issue":"24","key":"10.1016\/j.farma.2026.06.012_bb0130","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2146\/ajhp180564","article-title":"ASHP guidelines on handling hazardous drugs","volume":"75","author":"Power","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"10.1016\/j.farma.2026.06.012_bb0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4212\/cjhp.v72i1.2870","article-title":"Biological monitoring of 4 antineoplastic drugs in health care workers from 2 adult hospitals: a pilot study","volume":"72","author":"Chauchat","year":"2019","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.farma.2026.06.012_bb0140","first-page":"16","article-title":"Detection of contamination with antineoplastic agents in a hospital pharmacy department","volume":"14","author":"Sessink","year":"1992","journal-title":"Pharm Weekbl"},{"issue":"2","key":"10.1016\/j.farma.2026.06.012_bb0145","first-page":"251","article-title":"Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital","volume":"57","author":"Yoshida","year":"2013","journal-title":"Ann Occup Hyg"},{"key":"10.1016\/j.farma.2026.06.012_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchromb.2016.10.021","article-title":"Highly sensitive LC\u2013MS\/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application","volume":"1038","author":"Canal-Raffin","year":"2016","journal-title":"J Chromatogr B"},{"issue":"7","key":"10.1016\/j.farma.2026.06.012_bb0155","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00420-015-1026-1","article-title":"Antineoplastic drug contamination in the urine of Canadian healthcare workers","volume":"88","author":"Hon","year":"2015","journal-title":"Int Arch Occup Environ Health"},{"issue":"5","key":"10.1016\/j.farma.2026.06.012_bb0160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.farma.2011.10.007","article-title":"Exposici\u00f3n a f\u00e1rmacos citot\u00f3xicos en el personal sanitario","volume":"36","author":"\u00c1lvarez","year":"2012","journal-title":"Farm Hosp"},{"key":"10.1016\/j.farma.2026.06.012_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2022.152954","article-title":"Hazardous drugs (NIOSH'S list-group 1) in healthcare settings: also a hazard for the environment?","volume":"817","author":"Domingo-Echaburu","year":"2022","journal-title":"Sci Total Environ"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:41:56Z","timestamp":1788900116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S1130634326001686"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.06.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How safe is occupational exposure to citostatic drugs? Results from environmental and biological monitoring","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}